PF-184563

PF-184563
Clinical data
ATC code	none;
Pharmacokinetic data
Bioavailability	34%
Protein binding	69%
Elimination half-life	1.8h
Identifiers
	IUPAC name 8-Chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene;
CAS Number	748806-39-5 ;
ChemSpider	9412479 ;
ChEMBL	ChEMBL1837037 ;
Chemical and physical data
Formula	C21H23ClN6
Molar mass	394.91 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1CC2=C(C=CC(=C2)Cl)N3C(=NN=C3C4CCN(CC4)C5=CC=CC=N5)C1;
	InChI InChI=1S/C21H23ClN6/c1-26-13-16-12-17(22)5-6-18(16)28-20(14-26)24-25-21(28)15-7-10-27(11-8-15)19-4-2-3-9-23-19/h2-6,9,12,15H,7-8,10-11,13-14H2,1H3 ; Key:LXHAZNJVVVBJIF-UHFFFAOYSA-N ;
	(what is this?) (verify)

PF-184563 is a potent, selective non-peptidic antagonist of the V1a receptor.^[1] The compound was discovered by Pfizer in its Sandwich, Kent research center, as a potential treatment for dysmenorrhoea, an indication for which V1a antagonists have shown efficacy.^[2]

References

^ Johnson PS, Ryckmans T, Bryans J, Beal DM, Dack KN, Feeder N, Harrison A, Lewis M, Mason HJ, Mills J, Newman J, Pasquinet C, Rawson DJ, Roberts LR, Russell R, Spark D, Stobie A, Underwood TJ, Ward R and Wheeler S (October 2011). "Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability". Bioorganic. Med. Chem. Lett. (21): 5684–5687. doi:10.1016/j.bmcl.2011.08.038. PMID 21885275.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Brouard R, Bossmar T, Fournie-Lloret D, Chassard D and Akerlund M (2000). "Effect of SR49059, an orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea". Br. J. Obstet. Gynaecol. 5 (107): 614–619. doi:10.1111/j.1471-0528.2000.tb13302.x. PMID 10826575.{{cite journal}}: CS1 maint: multiple names: authors list (link)

This hormonal preparation article is a stub. You can help Wikipedia by expanding it.

[PMID21885275-1] Johnson PS, Ryckmans T, Bryans J, Beal DM, Dack KN, Feeder N, Harrison A, Lewis M, Mason HJ, Mills J, Newman J, Pasquinet C, Rawson DJ, Roberts LR, Russell R, Spark D, Stobie A, Underwood TJ, Ward R and Wheeler S (October 2011). "Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability". Bioorganic. Med. Chem. Lett. (21): 5684–5687. doi:10.1016/j.bmcl.2011.08.038. PMID 21885275.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[PMID10826575-2] Brouard R, Bossmar T, Fournie-Lloret D, Chassard D and Akerlund M (2000). "Effect of SR49059, an orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea". Br. J. Obstet. Gynaecol. 5 (107): 614–619. doi:10.1111/j.1471-0528.2000.tb13302.x. PMID 10826575.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[1]

[2]